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Hepatocyte growth factor (HGF) was initially identified in cultured hepatocytes and 
subsequently reported to induce angiogenic mitogen, morphogen, and antiapoptotic 
activity in various tissues. These properties suggest a potential influence of HGF on bone 
healing. We asked if gene transfer of human HGF (hHGF) into a fracture gap with a 
hemagglutinating virus of Japan-envelope (HVJ-E) vector promotes bone healing in 
rabbits.  
HVJ-E that contained either hHGF or control plasmid was percutaneously injected into 
the fracture gap of rabbit tibias on Day 14. The fracture gap was evaluated by 
radiography, pQCT, mechanical tests, and histology at Week 8. The expression of hHGF 
was evaluated by RT-PCR and immunohistochemistry at Week 3. Radiography, pQCT, 
and histology suggested the hHGF group had faster fracture healing. Mechanical tests 
demonstrated the hHGF group had greater mechanical strength. The injected tissues at 3 
weeks expressed hHGF mRNA by RT-PCR. hHGF-positive immunohistochemical 
staining was observed in various cells at the fracture gap at Week 3. The data suggests 
delivery of hHGF plasmid into fracture gap promotes fracture repair, and HGF could 


























The treatment of bone fractures has advanced rapidly in recent years. Various implants 
for treating fractures have been developed.3,20 However, complex fractures remain a 
challenge and often require prolonged fixation. External fixation is preferred by many 
surgeons method to stabilize such fractures. However, external fixators are still 
associated with nonunions, pin track infections, and contracture of adjacent joints, some 
of which relate to the length of the required immobilization.  
More rapid bone repair within the fracture gap would avoid the complications that result 
from prolonged immobilization. Moreover, Einhorn16 concluded enhancement of the 
fracture repair process would ensure rapid restoration of function. The ability of injured 
patients to return earlier to daily life would not only have a substantial economic impact 
on society, but would also improve the overall physical and mental wellbeing of the 
patients. Therefore, a compelling need still exists for a safe and effective way to enhance 
bone repair. 
Many studies report enhancement of fracture healing with hormones or growth factors, 
such as IGF-I,30 BMP,17, 29, 51 FGF-2,4, 10, 42 VEGF,13 and PTH.2 Recently, another growth 
factor called hepatocyte growth factor (HGF) functions as a powerful and versatile factor 
with angiogenesis, mitogen, morphogen, and antiapoptotic activity. HGF was originally 
identified from plasma and serum as a molecule that simulated DNA synthesis in rat and 
human hepatocytes in 1989.36, 37 Multiple studies subsequently confirmed the role of 
HGF in enhancing hepatocyte function.21, 25, 27, 28, 39, 45, 47, 49, 50, 52 However, little is known 

























many growth factors influence various tissues, the question arises as to whether HGF 
influences bone healing.  
We therefore hypothesized gene transfer of hHGF directly into fracture gaps using the 
HVJ-E vector would promote tibia fracture healing in radiograph, computer tomograph, 
mechanical test ,and histology in rabbits. Furthermore, we tested the mRNA and protein 
expression of hHGF to prove the effect of the injected gene.  
MATERIALS AND METHODS 
In a preliminary study we delivered high human HGF (hHGF) concentrations 
percutaneously and therefore less invasively than an open method to rabbit tibia fracture 
gaps. We utilized a novel, nonviral vector, the hemagglutinating virus of Japan envelope 
(HVJ-E), to deliver hHGF genes to fracture gaps. The HVJ-E vector is effective for gene 
transfer both in vitro and in vivo.26  Fracture models were prepared in 50 mature female 
Japanese white rabbits weighing 2.5 to 3 kg.  The rabbits were equally divided into two 
groups of 25 rabbits each, the hHGF group and the control vector group. Human HGF 
cDNA (2.2 kb) was inserted between the EcoRI and NotI gaps of the pUC-Sr expression 
vector plasmid to produce an hHGF expression vector. A pcDNA 3.1(-) plasmid DNA 
vector (Invitrogen, San Diego, CA) with the same structure, but lacking the hHGF cDNA, 
was used as a control vector.  On Day 7 after injection of HVJ-E, three rabbits in each 
group were assessed for hHGF mRNA. At 3 and 8 weeks postoperatively, two animals 
from each group were sacrificed for immunohistochemistry. At 8 weeks, the remaining 


























testing. The experimental protocol was approved by the Committee on the Ethics of 
Animal Experiments of Kanazawa University. 
HVJ (also known as Sendai virus) envelope vector was prepared as described 
previously.26 Briefly, the virus was purified by centrifugation and inactivated by UV 
irradiation, which disabled the replication capacity of the virus completely without 
affecting the cell membrane fusing capability of the envelope. HVJ envelope (5 AU) was 
mixed with 50 μg of either HGF or pcDNA3.1(-) plasmid DNA and 0.3% Triton-X 100. 
The suspension was then washed with balanced salt solution (BSS - 137 mM NaCl, 5.4 
mM KCl, 10 mM Tris-HCl; pH 7.6) and centrifuged (10,000 g, 10 min) at 4°C, and the 
pellet was resuspended in a final volume of 100 µl BSS for subcutaneous injection. The 
suspension was stored at 4°C until use. HVJ-E vector is commercially available from 
Ishihara Sangyo Co. Ltd. (Osaka, Japan). 
The rabbits were anesthetized with a subcutaneous injection of ketamine hydrochloride 
(35 mg/kg body weight; Sankyo Pharmaceutical, Tokyo, Japan), xylazine (5 mg/kg body 
weight; Bayer, Tokyo, Japan), and an intravenous injection of pentobarbital sodium (40-
50 mg/kg body weight; Abbott Laboratories, North Chicago, IL). A longitudinal skin 
incision was made on the anteromedial aspect of the right tibia, and the periosteum was 
carefully stripped of the surrounding soft tissue and fascia. Four half pins 2 mm in 
diameter (Stryker, Geneva, Switzerland) were inserted into the medial aspect of the tibia, 
perpendicular to its axis, and a unilateral external fixator of our design was applied. To 
simulate a fracture of the rabbit tibia,33, 40, 41 we created a 3-mm gap between the bone 




Althogh this model was not a fracture in essence, it was an osteotomy, healing process of  
























At postoperative Week 2, after induction of anesthesia with ketamine and xylazine, HVJ-
E (100 μL) containing either hHGF or pcDNA 3.1(-) plasmid DNA (n = 25 for each 
group) was percutaneously injected into the fracture gap with a 29-gauge needle (Terumo, 
Atsugi, Japan) under an image intensifier. The reason we chose postoperative Week 2 
was that there were many cells to introduce the gene at the fracture gap. 
On Day 7 after percutaneous injection of HVJ-E containing either hHGF or pcDNA 3.1 (-
) plasmid DNA (n = 3 for each group), the rabbits were euthanized and the tissue at the 
fracture gap and the surrounding muscle was harvested and prepared for reverse 
transcription-polymerase chain reaction (RT-PCR) to detect hHGF mRNA. The reason 
why we chose 7 days after delivery was that the maximum amount of mRNA from 
introduced gene was peaked at 5-7 days after the injection.Total RNA was isolated using 
acid guanidinium thiocyanate-phenol-chloroform and ethanol precipitation. RT-PCR was 
performed using an amplification reagent kit (TaqMan EZRT-PCR kit; Applied 
Biosystems, Alameda, CA) with primers specific for hHGF and rabbit GAPDH. The 
primer pairs for hHGF (sense primer, 5'-ACCCAAGCTGGCTAGCGT-3'; anti-sense 
primer, 5'-AGTGCTGGATCTATTTTGATTAGG-3') and rabbit GAPDH (sense primer, 
5'-GCGCCTGGTCACCAGGGCTGCTT-3'; anti-sense primer, 5'-
TGCCGAAGTGGTCGTGGATGACCT-3') 44 were used to amplify hHGF and rabbit 
GAPDH. PCR reactions of 40 cycles with annealing temperature of 62°C for 1 minute for 

























were performed. The PCR products (hHGF, 260 bp; GAPDH, 465 bp) were separated by 
electrophoresis in a 3% agarose gel and stained with ethidium bromide. 
At postoperative weeks 3 (for the confirmation of the protein expression) and 8 (for the 
period of the protein expression), two tibias, respectively, from each group were used for 
immunohistochemistry. Paraffin sections were treated with anti-hHGF monoclonal 
antibody (R&D Systems Inc., Minneapolis, MN; dilution 1:100), and peroxidase-
conjugated goat antimouse immunoglobulin (EnVision, DAKO, Carpinteria, CA) was 
used as the secondary antibody. To develop the color, a DAB kit (EnVision, DAKO) was 
used. The sections were counterstained with Mayer’s hematoxylin.  
To monitor bone formation, the fracture gaps of the hHGF group were compared to those 
of the control vector group by radiography at each postoperative time point (Fig 1A-B). 
The fracture gap was evaluated by comparing bone density of the hHGF and control 
groups (n = 20 for each group) on anteroposterior and medial-lateral radiographs with an 
aluminum step wedge (10 steps, 1 mm/step) on the same film. Radiographs were 
obtained weekly under anesthesia for 8 weeks after the operation. We (HT) evaluated the 
quantity of callus over the entire 3-mm gap between the proximal and distal native bone 
using Scion Image Beta-3b software for Windows (Scion Corporation, Frederick, MD). 
Briefly, the bone density of the gap was measured by interpreting the entire image in 
units of thickness of the aluminum plate by comparing it with the gradient of luminosity 
obtained from the aluminum wedge. The bone density is reported in units of aluminum 




For the quantitative evaluation of the healing process, 10 rabbits in each group were 
euthanized by an intravenous dose of sodium pentobarbital 8 weeks after surgery. After 
the soft tissues were dissected from the tibia and the external fixator was removed. The 
tibias were stored in gauze soaked in 0.9% saline solution at -20°C and thawed at room 
temperature before pQCT and mechanical analysis. A quantitative determination of callus 
development was performed with pQCT (XCT-Research SA+, Stratec, Pforzheim, 
Germany). A 3-mm gap bone section was analyzed with three consecutive transverse 
pQCT scans 0.77 mm thick, 2.5 mm apart, and with a pixel size of 0.1 × 0.1 mm. The 
XCT Series software package (Rev. 6.00B; Stratec, Pforzheim, Germany) was used to 
























2), and bone mineral 
density (mg/cm3) at the gap level. In order to assess progression of remodeling, areas of 
higher bone density (> 690 mg/cm3) within the callus were measured and separated from 
areas of low-mineral density. The mineral content and the area of this high-mineral-
density callus were calculated. The threshold of 690 mg/cm3 was selected because it 
corresponds to the lower level of cortical bone. Furthermore, electronic sections through 
the long axis of each tibia were created on 3-D reconstructed images. 
Both tibiae of each rabbit were mechanically tested using an electromechanical testing 
machine (model MZ-500D; Maruto Machine, Inc., Tokyo, Japan). A three-point bending 
test was performed at a rate of 2.5 mm/min with 100 kgf of weight axial load. The central 
loading point was adjusted toward the fracture gap. The lower loading points were 
separated 30 mm from each other. Failure load values and load-displacement curves were 
obtained for all samples. The stiffness of each unilateral tibia was calculated as the slope 

























mechanical data of the fractured unilateral tibia to the intact tibia (percent failure load and 
percent stiffness) were calculated.  
Ten rabbits in each group were euthanized 8 weeks after surgery, and the histology of the 
fracture gap was studied. Heparinized physiologic saline was perfused through both 
femoral arteries followed by perfusion with 4% paraformaldehyde solution in a 
phosphate buffer (pH 7.4). The tibias were fixed for 24 hours in the same solution. The 
tibias were then decalcified with 10% EDTA solution and embedded in paraffin. The 
specimens were sectioned at a 5-µm thickness parallel to the bone axis and stained with 
hematoxylin and eosin. 
Differences in the bone density, mineral contents, mineralized area, bone 
mineral density, failure load, and stiffness between control vector group and 
HGF group were determined by a student’s t test. 
RESULTS 
The administration of HVJ-E/hHGF or HVJ-E/pcDNA to the rabbits produced no 
obvious adverse effects such as sudden death or abnormal weight loss during the 8 weeks 
of the experiment.  
In radiographs, bony callus appeared on the lateral side at postoperative Week 2 in the 
control vector group and bridged the fracture gap at postoperative Week 3. After 3 weeks, 
the size of the bridging callus was reduced and the callus became gradually calcified at 
the fracture gap. At postoperative Week 8, however, corticalization was not sufficient to 



























vector group until postoperative Week 3. After that time point, the callus at the fracture 
gap became calcified to a greater extent and more rapidly than that of the control vector 
group. Furthermore, remodeling, especially corticalization and formation of the 
medullary canal, progressed in the hHGF group. At postoperative Week 8, remodeling in 
hHGF group was complete, and the fracture gap looked homogeneous when compared to 
the host bone.  
The bone density in the hHGF group was greatercompared to the control vector group at 
postoperative weeks 4 to 8 (p= 0.3675 ; week 2, p= 0.0099 ; week 4, p= 0.0002 ; week 6, 
p= 0.0093 ; week 8) (Table 1) (Fig 2). Mineral content in the hHGF group was greater (p 
= 0.006) at postoperative Week 8 compared to the control vector group (control vector 
group, 18.7 ± 4.7 mg/mm; hHGF group, 25.7 ± 5.4 mg/mm;) (Fig 3A). Mineralized 
callus area in the hHGF group was also greater (p = 0.015) at postoperative Week 8 
compared to the control vector group (control vector group, 19.4 ± 4.9 mm2; hHGF group, 
26.2 ± 6.4 mm2) (Fig 3B). In addition, bone mineral density in the hHGF group tended to 
be greater at postoperative Week 8 compared to the control vector group, however, there 
was no difference (p = 0.059) between the two groups (control vector group, 933.5 ± 67.3 
mg/cm3; hHGF group, 987.7 ± 52.7 mg/cm3) (Fig 3C). 3D-CT reconstructed images and 
axial images of specimens obtained 8 weeks after surgery were created (Fig 4A-B). The 
fracture gaps in the control vector specimen were not bridged completely with a partial 
defect of the cortical bone. However, no gap was observed in the fracture gap of the 
hHGF group (Fig 4A). In the axial view, the fracture gaps in the hHGF group had a 
circular, thick cortical bone. In contrast, the cortex in the control vector group had a 

























The mean ratio of failure loads of the hHGF group was greater (p = 0.037) than that of 
the control vector group (89.4 ± 17.5% versus 76.3 ± 9.1%, respectively) (Fig 5A). The 
hHGF-treated tibiae were relatively stiffer (p = 0.001) than those of the control group 
when both were compared to their contralateral controls (69.7 ± 6.5% versus 57.5 ± 
6.3%) (Fig 5B).   
At postoperative Week 8 in the hHGF group, the fracture gaps were completely 
remodeled with a firm cortex and a reconstructed medullary canal almost identical to that 
of normal bone. In contrast, a medullary canal was not observed in the control vector 
group. In place of a medullary canal, mature cartilage and new trabecular bone were 
present in the middle of the fracture gap, which was not remodeled sufficiently (Fig 6). In 
RT-PCR, expression of hHGF mRNA was detected only in the callus of hHGF group and 
in the surrounding muscle of neither group (Fig 7). Thus HVJ-E/hHGF was transfected 
locally into the fracture gap sufficiently to express mRNA. By immunohistochemistry, 
We observed expression of hHGF in immature cells, fibroblasts, osteoblasts, and 
osteocytes (Fig 8A). No immunohistochemical staining was observed in the surrounding 
muscle of the hHGF group. No hHGF-positive cells were observed in specimens from the 
control vector group. This indicates the HVJ-E/hHGF was transfected locally into the 
fracture gap at the level of protein. Human HGF expression was still observed at this time 
point, however, when expression at 8 weeks was compared to that at 3 weeks, hHGF 




























 HGF was originally identified from rat and human hepatocyte. Multiple studies 
subsequently confirmed the role of HGF in enhancing hepatocyte function. After that, 
HGF was recognized as a powerful and versatile factor with angiogenesis, mitogen, 
morphogen, and antiapoptotic activity in various tissues. The question arose as to whether 
HGF influences bone healing.  We therefore hypothesized gene transfer of hHGF directly 
into fracture gaps would promote bone healing in rabbit. This study had two major 
limitations. First, we followed up only eight weeks. Although this time period was chosen 
because the control model showed bone union and sufficient corticalization in radiograph 
at postoperatibe Week 8, our mechanical test data did not reach intact level. Different 
results may occur at later stages of healing. However, this study demonstrates bone 
healing differences resulting from HGF, especially at early stage. Second, we did not 
confirm the duration of hHGF gene expression. Because, on clinical setteing, gene 
therapy always accompanies the problem of its safety, we should ascertain its safety until 
at least the end of expression. We gave the priority to economic and practically reasons. 
Our data suggest percutaneous injection of HVJ-E/hHGF into tibial fracture gaps 
effectively promotes bone repair. Consequently, the treatment time for fractures could be 
shortened when the hHGF gene is administered during the early stages of fracture repair. 
These data indicate the high potential of hHGF gene therapy using the HVJ-E vectors for 
treatment of bone fractures.   
Some osteogenetic factors have been used as therapeutic molecules for fracture healing 
and promote fracture repair. HGF, however, has not been used for this purpose to date. 
Many papers have been published describing therapeutic uses of HGF for various 




impairment,39 nerve injury,27 and spinal cord injury.45 Notably, HGF plasmid delivery for 
























Recently, it was demonstrated that HGF along with vitamin D promoted growth and 
differentiation of human mesenchymal cells into osteogenic cells.12 Later, it was reported 
HGF enhanced osteoblast differentiation in vitro.22 It has also been reported HGF 
contributes to fracture repair by inducing the expression of BMP receptors during the 
early phase of fracture repair.24 Our data support the previous results that the use of HGF 
for fracture repair will induce the expression of BMPR, which will differentiate 
mesenchymal cells into osteoblasts and osteoblasts into ossification. Based on these 
observations, the use of HGF together with other factors such as BMP or vitamin D could 
enhance fracture healing more rapidly. This possibility should be investigated in future 
studies. 
Gene delivery to bone has been accomplished by several vectors, including adenovirus, 
retrovirus, adeno-associated virus (AAV), lentivirus, and herpes simplex virus (HSV). In 
this study, we employed the HVJ-E vector system as the delivery method for bone 
fracture gaps. HVJ-E is a novel vector system that converts inactivated HVJ into a gene 
transfer vector by introducing plasmid DNA directly into inactivated HVJ particles after 
treatment with a mild detergent and centrifugation in the presence of plasmid DNA.26 
Previous studies demonstrated the successful delivery of DNA to cultured cells and 
animal tissues such as the inner ear,39 liver, skin, uterus, lung, eye, tumor tissues,26 and 
brain.46 HVJ-E is a nonviral vector that is generally less efficient than other viral delivery 




In principle, gene delivery is performed in two ways, in vivo or ex vivo.8, 9, 14 In-vivo 
gene delivery is a direct approach, where the vector is injected directly into the specified 
target tissue. Ex vivo is an indirect approach, where the therapeutic gene is delivered 
outside the body to various cells grown in culture prior to implantation into the body. In-
vivo gene delivery involves directly delivering the gene into a specific anatomic gap. The 
advantages of this method are that it is a simple technique that favors its transfer into a 
clinical application, and that it has the potential for lower costs. The disadvantages are the 
























14 Ex-vivo gene transfer is considered safer because transfected cells are 
introduced into the body, and safety tests are possible before introduction. However, it is 
technically more complex and more expensive. 
We used gene delivery rather than protein delivery. Gene therapy has potential 
advantages over protein delivery due to: (1) long-term expression of the protein from the 
delivered gene, (2) high local concentration of protein expression, (3) low cost of 
manufacture, (4) reduced systemic effects, and (5) longer shelf life and easier storage of 
vectors.31, 32, 38, 48 Ido23 reported recombinant hHGF administered intravenously was 
rapidly decreased in serum with a short half-life of 2.4 min. We detected expression of 
hHGF 6 weeks after the injection of plasmid. Therefore, gene transfer of HGF plasmid is 
expected to generate much longer expression of HGF than direct administration of HGF 
protein. Yoshimura52 also demonstrated gene transfer of HGF plasmid markedly 
increased cerebral blood flow in the ischemic brain, whereas a single injection of 




























 However, therapeutic gene therapy for bone regeneration with a nonviral vector 
has never been demonstrated. Egermann et al15 reported inflammation due to an immune 
reaction to adenovirus vectors caused severe retardation of bone formation. Similar 
results occurred with injection of Ad-BMP-2 into muscles of immunocompetent rats, 
causing poor bone formation and an inflammatory response at the injection gap.1  
Furthermore, a small number of studies address direct percutaneous injection of a gene to 
a fracture gap.7, 8, 43 Gene transfer by direct percutaneous injection leading to endogenous 
bioactive protein expression offers the potential advantage of simple direct delivery 
without the requirement for a carrier or surgery and could be used to treat closed fractures 
in clinical cases. Rundle43 also performed percutaneous injection of the BMP-4 gene with 
a retroviral vector into the subperiosteum, which required the deposit of all vector within 
the periosteum while avoiding the muscle. Therefore it was technically difficult and not 
practical. Percutaneous injections of gene to muscle are widely used to promote bone 
repair due to the high efficiency and ease of transfection and longer duration of gene 
expression.1, 11, 35 With intramuscular injections, however, the area of gene expression is 
uncertain, which raises questions about the effect of gene expression at the fracture gap. 
Furthermore, the immune response differs between intraosseous and intramuscular gaps, 
as the muscle has a stronger immunologic reaction.6  
Our data suggests HGF promotes fracture healing in rabbit tibia and in-vivo gene therapy 
using HVJ-E/hHGF effectively enhances bone formation in fracture healing. Utilization 






wellbeing of patients. In the future, the safety evaluation of this gene therapy technique 
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Fig 1A-B. (A) A series of anteroposterior radiographs taken of the hHGF group (H) and 
control groups (C) from each single animal show faster callus formation at the 3-mm gap 
in the hHGF group. (B) A series of mediolateral radiographs taken of the hHGF group 
(H) and control groups (C) from each single animal show faster remodeling at the 3-mm 
gap in the hHGF group. 
 
Fig 2. The effect of hHGF plasmid on bone healing was determined by bone density of 
the 3-mm gap. The results of the bone density are given in units of aluminum thickness  
 
Fig 3A-C. (A) At postoperative Week 8 the mineral content (mean ± SD, p = 0.0061) 
was higher in the hHGF group (H) than in the control vector group (C). (B) Mineralized 
callus area at postoperative Week 8 (mean ± SD, p = 0.015) was higher in the hHGF 
group (H) than in the control vector group (C). (C) Bone mineral density 8 weeks after 
the operation (mean ± SD)  in the hHGF group tended to be greater compared to the 
control vector group (C). There was no difference (p = 0.059) between the two groups.  
  
Fig 4A-B. (A) A reconstruction image of whole tibia at postoperative Week 8 shows 
complete bridging in the hHGF group (H), and not in the control vector group (C) with a 
partial defect in cortical bone. (B) An axial image at the gap level 8 weeks after the 
operation shows thick, circular cortical bone in the hHGF group (H), and not in the 





Fig 5A-B. (A) Mean percentage of failure load at postoperative Week 8 (mean ± SD, p  = 
0.0375) was higher in the hHGF group (H) than in the control vector group (C). (B) Mean 
percentage stiffness at postoperative Week 8 (mean ± SDM,p = 0.0011) was stronger in 
the hHGF group (H) than in the control vector group (C).  
 
Fig 6. Representative longitudinal histologic sections of the 3-mm gap at postoperative 
Week 8 are shown. The arrows indicate the original 3-mm defect region (top row). 
Magnified histology of 3-mm gap (bottom row). The gap in the control vector group (C) 
had a trabecular bone in the middle of the fracture gap, meanwhile in the hHGF group 
(H), a firm cortex and a reconstructed medullary canal were observed. (Stain, 
Hematoxilin-Eosin stain; original magnification, ×1 for left side and ×40 for right side) 
 
Fig. 7. RT-PCR analysis demonstrated the expression of hHGF mRNA in the injected 
callus and the surrounding muscle of both groups. hHGF mRNA was specifically 
detected in the callus of the hHGF group (H), but was not detected in the callus and 
muscle of the control vector group, or in muscle of the hHGF group. 
 
Fig. 8A-B. (A) Immunohistochemistry of hHGF at the fracture gap at postoperative 
Week 3 (1 week after the injection of plasmid)(Stain, Immunohistochemistry of hHGF ; 
original magnification, ×400). In the hHGF group (H), hHGF expression was markedly 
observed in immature cells, fibroblasts, osteoblasts, and osteocytes. No 
immunohistochemical staining was observed in specimens from the control vector group 




(1 and 5 weeks after the injection of plasmid) (Stain, Immunohistochemistry of hHGF ; 
original magnification, ×400). hHGF expression was still observed at postoperative Week 
8; however, it decreased compared to that of postoperative Week 3. 
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Fig. 8B
